ホーム > 製品 > 抗体 > バイオシミラー

Research Grade Xeligekimab (HS856116)

データシート製品共有情報コピー

Research Grade Xeligekimab

Research Grade Xeligekimab

Research Grade Xeligekimab

Research Grade Xeligekimab

Research Grade Xeligekimab

Research Grade Xeligekimab

価格(USD): $

スペック:

100ug
1mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート

概要

カタログ番号	HS856116
説明	Xeligekimab (HS856116) is a research-grade recombinant antibody targeting CTLA-8. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性	Human
アプリケーション	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種	Humanized
アイソタイプ	IgG4-kappa
発現システム	Mammalian Cells
クローン性	Monoclonal
ターゲット	CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A
エンドトキシンレベル	Please contact the lab for this information.
純度	>95% purity as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	Q16552
形態	Liquid
保存バッファー	0.01M PBS, pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
別名	GR1501, GR-1501, GR15012382921-73-3
背景	Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx). 1. Boisson, B. et al. (2013) Immunity 39, 676-86. PMID: 24120361 2. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633 3. Wright, JF. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 2799-805. PMID: 18684971 4. Liu, C. et al. (2009) Science signaling 2, ra63. PMID: 19825828 5. Puel, A. et al. (2011) Science (New York, N.Y.) 332, 65-8. PMID: 21350122 6. Fossiez, F. et al. (1996) The Journal of experimental medicine 183, 2593-603. PMID: 8676080
注意事項	For research use only. Not suitable for clinical or therapeutic use.

イメージ

SDS-PAGE

SDS-PAGE for Research Grade Xeligekimab.
Bioactivity

Detects recombinant human IL17A (Catalog No: HS856011) in indirect ELISA
Western blot

Western blot analysis was performed using anti-IL17A monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human IL17A (Catalog No: HS856012)
Lane 2: negative control

参考文献

データシート

Research Grade Xeligekimab.pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

レコメンデーション

お問い合わせカスタムクォート、大量リクエストおよびその他の問題については

メール: support@abinScience.com

ディストリビューターリスト

Research Grade Xeligekimab